Representative before the EPO

Employment test 51 - 200 employees
Company dna mathys and squire llp
no operation time available
Headquarter in London and 5 offices
active in Legal Services and Matchmaking and Trading

We have observed 32 EP applications Harvey Vaughan John Adams has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after November 16, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12804528

INHIBITORS OF T-CELL ACTIVATION

IPC classification:
A61K 39/395
Applicant:
Genzyme Corporation
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP11861101

NPP1 FUSION PROTEINS

IPC classification:
C12N 15/86, C12N 15/63, C12N 15/62, C07K 19/00, A61P 9/10, A61P 3/10
Agent:
Deborah Mary Hart, Kilburn & Strode LLP
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
GRANT OF PATENT INTENDED
EP13173895

Intraventricular enzyme delivery for lysosomal storage diseases

IPC classification:
A61K 38/46
Applicant:
Genzyme Corporation
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP12173124

Method for producing plant seed containing endophytic micro-organisms

IPC classification:
A01N 25/00, C12R 1/01, C12N 1/04, C05F 11/08, A01N 63/04, A01C 1/06
Applicant:
AIT Austrian Institute of Technology GmbH
Agent:
Sonn & Partner
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP12755254

METHODS AND COMPOSITIONS FOR TREATING DEPRESSION USING CYCLOBENZAPRINE

IPC classification:
A61K 45/06, A61K 31/55, A61K 31/137, A61P 25/24
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP14150948

Drug loaded polymeric nanoparticles and methods of making and using same

IPC classification:
A61K 47/48, A61K 47/34, A61K 33/24, A61K 31/337, A61K 9/16, C08G 63/672, C08G 63/668
Agent:
Pfizer Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Jennifer Lucy Harris, Kilburn & Strode LLP
Status:
EXAMINATION REQUESTED
EP13188102

Antibody purification

IPC classification:
C07K 16/00, C07K 1/18
Applicant:
AbbVie Biotechnology Ltd
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13188107

Antibody purification

IPC classification:
C07K 16/00, C07K 1/18
Applicant:
AbbVie Biotechnology Ltd
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13877986

HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME

IPC classification:
A61K 39/00, G01N 33/68, C12N 5/10, C07K 16/24, C07K 1/18
Applicant:
AbbVie Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Graham James Lock, Fry Heath & Spence LLP
Status:
APPLICATION WITHDRAWN
EP13785752

MODULATED LYSINE VARIANT SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME

IPC classification:
C12N 5/00, C07K 16/28, C07K 16/00
Applicant:
AbbVie Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Graham James Lock, Fry Heath & Spence LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13786072

LOW ACIDIC SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME

IPC classification:
C07K 16/24
Applicant:
AbbVie Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Graham James Lock, Fry Heath & Spence LLP
Status:
GRANT OF PATENT INTENDED
EP14186885

Methods for treating psoriasis

IPC classification:
A61K 38/00, A01N 37/18
Applicant:
AbbVie Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12742453

CENTRIFUGE ROTOR FOR SEPARATION AND PROCESSING OF COMPLEX FLUIDS

IPC classification:
G01N 27/07, B04B 5/02
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14195388

Engineered nucleic acids and methods of use thereof

IPC classification:
C12N 5/07, C07H 21/02
Applicant:
Moderna Therapeutics, Inc.
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Hoffmann Eitle PartmbB
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13712650

METHODS TO CONTROL PROTEIN HETEROGENEITY

IPC classification:
C12N 5/10
Applicant:
AbbVie Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
APPLICATION WITHDRAWN
EP15154238

Nucleic acids and proteins from streptococcus group A & B

IPC classification:
C07K 14/315
Applicant:
Novartis Vaccines and Diagnostics Srl
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15152668

Isolation and purification of antibodies using Protein A affinity chromatography

IPC classification:
C07K 16/24, C07K 16/00, C07K 1/16
Applicant:
AbbVie Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP15165128

HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA

IPC classification:
A61K 39/395, G01N 33/68, C12N 15/64, C12N 15/13, C12N 15/09, C12N 5/10, C12N 1/21, C07K 16/24
Applicant:
AbbVie Biotechnology Ltd
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
GRANT OF PATENT INTENDED
EP15165134

HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA

IPC classification:
A61K 39/395, G01N 33/68, C12N 15/64, C12N 15/13, C12N 15/09, C12N 5/10, C12N 1/21, C07K 16/24
Applicant:
AbbVie Biotechnology Ltd
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
GRANT OF PATENT INTENDED
EP15165138

HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA

IPC classification:
A61K 39/395, G01N 33/68, C12N 15/64, C12N 15/13, C12N 15/09, C12N 5/10, C12N 1/21, C07K 16/24
Applicant:
AbbVie Biotechnology Ltd
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
GRANT OF PATENT INTENDED
EP15165123

HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA

IPC classification:
A61K 39/395, G01N 33/68, C12N 15/64, C12N 15/13, C12N 15/09, C12N 5/10, C12N 1/21, C07K 16/24
Applicant:
AbbVie Biotechnology Ltd
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
GRANT OF PATENT INTENDED
EP15165133

METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES

IPC classification:
A61K 39/395, A61K 31/519, C07K 16/24, A61P 37/06, A61P 19/02
Applicant:
AbbVie Biotechnology Ltd
Agent:
Se√°n Malcolm Walton, Mewburn Ellis LLP
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
PATENT GRANTED
EP15157149

Treatment of TNF alpha related disorders

IPC classification:
A61K 39/395, C07K 16/24
Applicant:
AbbVie Biotechnology Ltd
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12746845

METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY

IPC classification:
A61P 3/06, A61K 38/46
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Kristina Cornish, Kilburn & Strode LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP15169378

Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion

IPC classification:
A61K 31/425, A61K 9/20, A61K 9/14
Applicant:
AbbVie Inc
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Reitstötter Kinzebach & Partner GbR
Status:
The patent has been granted
EP13785756

PURIFICATION OF PROTEINS USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY

IPC classification:
C07K 1/34, C07K 1/22, C07K 1/18, C07K 1/16, C07K 1/36, C07K 16/24, C07K 1/20, A61K 39/395
Applicant:
AbbVie Inc
Agent:
Multiple attorneys, Mathys & Squire LLP
Status:
APPLICATION WITHDRAWN
EP14200334

ISOLATED RECOMBINANT HUMAN N-GLYCOSYLATED LYSOSOMAL ACID LIPASE

IPC classification:
C12N 9/18, A61K 38/38, C12N 9/20, A61K 31/194, A01K 67/027, A61P 3/06, A61K 31/135, A61K 31/397, A61K 31/366, A61K 38/46
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP14715521

COMPOSITIONS AND METHODS OF ALTERING CHOLESTEROL LEVELS

IPC classification:
A61K 31/70, C12N 15/12, C12N 15/67, A61K 48/00, C07K 14/705, C12N 15/63
Applicant:
Moderna Therapeutics, Inc.
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Agent:
Hoffmann Eitle PartmbB
Status:
EXAMINATION IN PROGRESS
EP15178740

CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA

IPC classification:
A61K 39/00, C12N 9/64, A61K 45/06, C07K 16/18, C07K 14/745, A61K 47/48, A61K 38/36, C12P 21/08, A61K 39/395
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP16157001

FORMULATION OF BORONIC ACID COMPOUNDS

IPC classification:
A61P 29/00, A61P 35/00, A61K 31/69, A61K 38/05, C07K 5/078, C07F 5/04, C07F 5/02
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP16198524

ADALIMUMAB FOR USE IN THERAPY OF RHEUMATOID ARTHRITIS

IPC classification:
A61K 31/519, A61P 19/02, A61P 37/06, A61K 39/395, C07K 16/24
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
The application has been published
EP17167946

FIBRONECTIN CRADLE MOLECULES AND LIBRARIES THEREOF

IPC classification:
C07K 14/78, C07K 16/42, C07K 16/40, C07K 16/18
Applicant:
University of Chicago
Applicant:
Novartis AG
Agent:
Harvey Vaughan John Adams, Mathys & Squire LLP
Status:
The application has been published

Please Sign in to use this feature